NVSD Stock Price and Chart — BCBA:NVSD — TradingView

Key facts today

Novartis (NOVN) started building a 700,000 sq ft manufacturing hub in North Carolina in 2026, part of its $23 billion U.S. investment in manufacturing and R&D; timeline and capacity noted.

Analyze the impact Analyze the impact

Key stats

Upcoming earnings

Details

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

NVS — Healthcare Leader Building Structure Novartis is showing an interesting structure within the Healthcare sector. After a strong prior uptrend, price has been consolidating inside a clear range between roughly 142 and 155. The lower boundary around 141.96 has acted as an important support area, while the upper range near 155–156 is the

by SniperAlphaResearch

Novartis Wave Analysis – 10 December 2025 - Novartis reversed from strong resistance level 133.35 - Likely to fall to support level 128.00 Novartis recently reversed up from the resistance area between the strong resistance level 133.35 (which has been reversing the price from the start of October) and the upper daily Bollinger Band. The

Novartis Increases Purchase of Avidity Biosciences Novartis Strengthens Its Rare Diseases Strategy with the Purchase of Avidity Biosciences By Ion Jauregui – Analyst at ActivTrades Novartis (SWX: NOVN) has taken an important step to strengthen its presence in therapies for rare diseases. The company announced the acquisition of Avidity Bioscien

NVS Bullish Continuation Long This looks super bullish If we get a flat to lower open tomorrow, would be a good market entry Best entry price around 110-108 TP1 133 TP2 154 This is a longer term play I would not expect this to play out in a couple weeks

by Profit44life

Novartis Wave Analysis –5 September 2025 - Novartis broke resistance area - Likely to rise to resistance level 132.00 Novartis recently opened with a sharp upward gap breaking the resistance area between the resistance level 128.00 (top of the previous impulse wave iii) and the resistance trendline of the daily up channel from May. The

Novartis | NVS | Long at $99.00 As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is

by WorthlessViews

NVS 1H Swing Long Conservative Trend Trade Conservative Trend Trade + long impulse + 1/2 correction + T2 level + support level - biggest volume 2Sp- Calculated affordable stop limit 1 to 2 R/R within 1H range take profit Daily Trend "+ long impulse + 1/2 correction + JOC level + support level - above 1/2 of entire 1D wave at the support le

by MishaSuvorov

Investing in Health: Reasons Why Novartis AG Stock Stands Out In an era where health is wealth, and the global healthcare sector is booming like never before, savvy investors are looking for opportunities that promise growth and a meaningful impact on people’s lives. Enter Novartis AG—a powerhouse in pharmaceuticals that’s not only redefining treatments but al

by AlfonsoMoreno

NVS Novartis AG Options Ahead of Earnings Analyzing the options chain and the chart patterns of NVS Novartis AG prior to the earnings report this week, I would consider purchasing the 110usd strike price Calls with an expiration date of 2024-8-16, for a premium of approximately $3.30. If these options prove to be profitable prior to the ear

Novartis Strikes $1.01 Bln Deal with Arvinas for Prostate Drugs Novartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Oscillators

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Oscillators

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Summary

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Moving Averages

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Moving Averages

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds

Maturity dateMar 18, 2056

Coupon5.70% (Fixed)

Maturity dateAug 14, 2050

Coupon2.75% (Fixed)

Maturity dateMar 18, 2046

Coupon5.60% (Fixed)

Maturity dateSep 18, 2054

Coupon4.70% (Fixed)

Maturity dateNov 5, 2045

Coupon5.20% (Fixed)

Maturity dateNov 5, 2055

Coupon5.30% (Fixed)

Maturity dateMay 6, 2044

Coupon4.40% (Fixed)

Maturity dateNov 20, 2045

Coupon4.00% (Fixed)

Maturity dateSep 21, 2042

Coupon3.70% (Fixed)

Maturity dateMar 18, 2036

Coupon4.90% (Fixed)

Maturity dateNov 5, 2035

Coupon4.60% (Fixed)

See all NVSD bonds